CANCER TRIGGER ARRESTED BY MOLECULAR HANDCUFFS

Main Menu | News By Date | News By Supplier | News By Category | About Us

CANCER TRIGGER ARRESTED BY MOLECULAR HANDCUFFS
07 April 2007 - University of Bristol

A molecule that promotes cell growth, and is frequently increased in different types of tumours, can be restrained by a molecular version of handcuffs, raising the prospect of a new way of treating the disease according to new research from the University of Bristol, funded by Cancer Research UK.

Professor Bass Hassan and colleagues were able to lock up a protein called IGF2 (Insulin-like growth factor 2) which helps control growth in all normal cells but when overproduced makes cells grow too large and too fast. In humans, increased levels of IGF2 are associated with a higher relative risk of bowel cancer. The scientists used a molecule that binds strongly to IGF2 to capture it and rescue cells from its effects.

This research demonstrates that the principle of using this method to ‘trap’ cancer-driving molecules works. The next step will be to develop clinical drugs that take advantage of similarly natural and non-toxic traps. If successful, such drugs could make a major difference to the lives of many people with cancer.

Professor Bass Hassan, senior author of the report, said: “We knew that having too much IGF2 in cells promotes the development of tumours, and wanted to find out if we could just stop the molecule from working rather than destroying it.

“We took part of another protein that binds exclusively to IGF2 and found it blocked IGF2’s action, leaving other molecules free to go about their business. We’re already in the process of modifying the trap to make it even better for use as a therapeutic drug. If all goes well we will be able to start early clinical trials in the next two or three years.”

Professor John Toy, medical director of Cancer Research UK, said: “We are constantly searching for ways to halt cancer-promoting agents. When they are in the body, this has to be done without affecting important molecular processes that keep us healthy.

“Professor Hassan’s team has shown a viable and potent method of blocking IGF2’s effects. But, of course, it is too early to predict whether it will work as a treatment for cancer patients. However, every successful drug has had to start at the stage of showing it works in principle. Many years of further research are now needed to reveal the true potential of this approach.”

Bowel cancer
Bowel cancer includes cancers of the colon and rectum. It is the third most common type of cancer in the UK (excluding non-melanoma skin cancer), with nearly 35,000 cases diagnosed each year. It is the second most common cancer in UK women. For more information, visit: www.cancerhelp.org.uk.

Up to 80 per cent of cases of colorectal cancer may be preventable by changes in diet. Visit www.reducetherisk.org.uk to find out how to lower your risk of developing many forms of cancer.

Cancer Research UK
Cancer Research UK's vision is to conquer cancer through world-class research. The charity works alone and in partnership with others to carry out research into the biology and causes of cancer, to develop effective treatments, improve the quality of life for cancer patients, reduce the number of people getting cancer and to provide authoritative information on cancer.

Cancer Research UK is the world's leading independent charity dedicated to research on the causes, treatment and prevention of cancer.

http://www.bris.ac.uk

About: University of Bristol
The University College of Bristol opened in 1876, after six years of discussions and controversy, in a bid to bring university culture to the provinces. It was the first college in the country to admit men and women on an equal footing.

The University’s Research and Enterprise Development (RED) division was launched in 2000 to stimulate and support an entrepreneurial culture and encourage the growth of technology-based business.

2003 saw the completion of the Dorothy Hodgkin building, named after the University’s fifth Chancellor. The £18 million building is dedicated to research in neuroendocrinology. 2003 also saw the opening of the University’s £5 million Centre for Sport, Exercise and Health.

Work on a new, state-of-the-art engineering building is due to be completed in early 2004. The £20 million BLADE project (Bristol Laboratory for Advanced Dynamics Engineering) will bring together the Engineering Faculty’s six departments to establish Europe’s most advanced dynamics engineering research facilities.

More News:
  • For April 2007
  • From University of Bristol
  • For Superconductors